II. Pathophysiology
-
Antiphospholipid Antibodies bind cell membrane phospholipids (including vascular endothelium)
- Antibody binding triggers inflammatory and prothrombotic changes
- Increases risk of recurrent thrombosis of any size vessel
- Core features include arterial thrombosis, venous thrombosis and Recurrent Pregnancy Loss
- Highly associated with Systemic Lupus Erythematosus (SLE)
- However, 60% of cases are not related to SLE
III. Risk Factors
-
Rheumatologic Conditions
- Systemic Lupus Erythematosus (40% of cases)
- Rheumatoid Arthritis (20% of RA patients are APLA positive)
-
Genetic predisposition
- Inherited Coagulopathy
- Various HLA markers
- Infections
- Medications
- Other factors
- Recurrent Pregnancy Loss (20% are APLA positive)
IV. Associated Conditions
- Major clinical associations
- Venous thrombosis
- Arterial thrombosis
- Recurrent Pregnancy Loss
- Thrombocytopenia
- Hemolytic Anemia
- Other clinical associations
- Heart Valve abnormality (esp. mitral and aortic valves)
- Positive Coombs tests
- Livedo Reticularis
- Migraine Headaches
- Leg ulcers
- Myelopathy
- Chorea
- Pulmonary Hypertension
- Avascular necrosis
V. Labs
-
Antiphospholipid Antibodies (APLA)
- Background
- Up to 10% of healthy patients are APLA positive at low titers
- However persistently high titers occur in less than 1% of healthy patients
- APLA positive status is based on at least 1 of 3 markers positive
- Positive tests should be confirmed with a second test at >=12 weeks after inital test
- Risk increases with the number of positive markers
- Up to 10% of healthy patients are APLA positive at low titers
- Anticardiolipin Antibody IgG and IgM (most sensitive test)
- IgG > 20 GPL is positive (>40 GPL are associated with increased thrombotic events)
- IgM > 20 MPL units is positive
- Possibly IgA positive
- Anti-B2-Glycoprotein I Autoantibodies
- Lupus Anticoagulant (most specific test, but Test Sensitivity only 20%)
- Background
- Other lab findings
- Partial Thromboplastin Time (PTT) prolonged
- Autoantibodies are present in 5% of healthy patients
- False PositiveVDRL (30-40%)
- Cytopenias
VI. Diagnosis: Revised Sapporo Criteria (2006)
- Diagnosis requires at least 1 clinical AND 1 lab criteria
- Clinical Criteria (at least one required)
- Vascular Thrombosis (one or more events)
- Arterial thrombosis OR
- Deep Vein Thrombosis (but NOT Superficial Thrombophlebitis) OR
- Small vessel thrombosis
- Recurrent Pregnancy Loss
- Unexplained fetal death at >10 weeks OR
- Premature birth <34 weeks due to PIH or placental insufficiency OR
- Three of more serial Spontaneous Abortions <10 weeks without other cause (e.g. chromosomal, anatomic, hormonal)
- Vascular Thrombosis (one or more events)
- Lab Criteria
- At least 1 of 3 Positive APLA (at high titers) by two tests spaced at least 12 weeks apart
VII. Prevention: Thrombotic Complications
-
Anticoagulation
-
Warfarin
- Moderate to high dose (INR >2 to 3) is protective
- Low dose (INR <1.9) does not prevent thrombosis
-
Low Molecular Weight Heparin (LMWH)
- May be used for APLA in pregnancy
-
Aspirin
- Protects against pregnancy loss (in those with multiple losses)
- Does not protect against thrombosis
-
Warfarin
-
Systemic Lupus Erythematosus and APLA positive
- Hydroxychloroquine
- Consider Aspirin prophylaxis
- Avoid factors predisposing to thrombosis
- Avoid Oral Contraceptive use
- Avoid Immobility
- Modify atherosclerotic risk factors
VIII. Complications
- See Associated Conditions above
- Catastrophic Anti-Phospholipid Antibody Syndrome (CAPS)
IX. Resources
- Not So Benign Antiphospholipid Antibody Syndrome (Hematologist)